Navigation Links
NicOx Reports Results for the First Three Quarters of 2008
Date:10/22/2008

SOPHIA ANTIPOLIS, France, October 22 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today reported financial results for the nine months ended September 30, 2008.

Key highlights of the third quarter of 2008:

- Positive top-line results from the 302 study for naproxcinod. The study

met all three co-primary efficacy endpoints at week-13 (p<0.001) and

naproxcinod 750 mg bid comfortably met the main secondary endpoint of

non-inferiority to naproxen 500 mg bid at week-13 and 26. Blood

pressure data from the 302 study also supported naproxcinod's non-

detrimental effect on blood pressure.

- Good overall long term safety demonstrated for both doses of

naproxcinod in the 301 extension study, with no unexpected safety

findings. In addition, the patients' mean blood pressure remained

stable for the 52 weeks following the completion of the 301 study,

suggesting that naproxcinod does not increase blood pressure over time.

- Exclusive agreement signed with Capsugel, the leading

producer of two-piece capsules, for the commercial manufacture of

naproxcinod capsules. Capsugel will be responsible for the formulation

and encapsulation of naproxcinod API.

- Enrollment of 417 osteoarthritis patients with controlled

hypertension successfully completed in two Ambulatory Blood Pressure

Monitoring (ABPM) trials, the 111 and 112 studies. These trials are

designed to assess the 24-hour blood pressure profile of naproxcinod,

in comparison to ibuprofen and naproxen.

- PF-03187207 demonstrated an improvement over Xalatan(R) 0.005% in a

Japanese phase 2 study in glaucoma, although the primary endpoint

at day 28 was not met. NicOx is currently discussing the rights to

PF-03187207 with Pfizer to allow its potential continued development

and commercialization, following Pfi
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules
2. NicOx Announces Departure of Damian Marron for CEO Position
3. NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
4. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
5. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
6. NicOx Opens U.S. Headquarters in New Jersey
7. Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months
8. Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares.
9. Amylin Pharmaceuticals Reports Third Quarter Financial Results
10. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
11. Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... College, PA (PRWEB) August 27, 2014 ... Simulation Software with new features for the biomedical ... is an enhanced Biological Thermal Sensor, exclusive to the ... a specialty version of XFdtd, developed to calculate the ... export functionality has been added to all versions to ...
(Date:8/26/2014)... Scientists have developed what they believe is the ... made in sheets only three atoms thick. , ... two of these single-layer semiconductor materials can be ... a heterojunction. This result could be the basis ... diodes, or LEDs, and solar technologies. , "Heterojunctions ...
(Date:8/26/2014)... LONDON , Aug. 26, 2014 An ... gene structures of all Mers CoV virus ... Replikin structures back to 2012.  This conservation and sharing ... of a Synthetic Mers CoV Blocker-Vaccine™ candidate, as it did ... Shrimp vaccine, both of which have been found to ...
(Date:8/26/2014)... argument has just been added to the growing ... as the next big thing in the high-tech ... materials. An international collaboration of researchers led by ... (DOE),s Lawrence Berkeley National Laboratory (Berkeley Lab) has ... transfer in photo-excited MX2 materials. The recorded charge ...
Breaking Biology Technology:Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 2Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 3Scientists craft atomically seamless, thinnest-possible semiconductor junctions 2Competition for graphene 2
... OmniSonics Medical,Technologies, Inc., a developer of advanced ... disease, announced today that it has enrolled its,first ... I is a prospective,multi-centered U.S. registry study of ... percutaneous mechanical,thrombectomy of acute deep vein thrombosis (DVT). ...
... Signalife, Inc. (Amex:,SGN - News) announced earlier ... financial commitments with respect to acquisitions of the,Company,s ... internationally, including in Japan, other parts of Asia ... the Company,s President and CEO, stated: "I anticipate,closing ...
... ... Surveillance System, EL SEGUNDO, Calif., March 17 ... has been awarded a,task order from the Centers for Disease Control ... System (NEDSS) Base System (NBS). The system helps the CDC,manage and ...
Cached Biology Technology:First Patient Enrolled in SONIC I Registry of OmniSonics Medical Technologies' OmniWave(TM) Endovascular System 2Signalife Sees Accretive Purchase and Financial Commitments 2CSC Continues Support of Centers for Disease Control and Prevention Through New Task Order 2
(Date:8/26/2014)... the University of Liverpool has recommended investing in dog owner ... and problems such as obesity in both people and their ... 1990, the researchers found that access to dog-friendly walking environments ... people to get out and take more exercise with their ... don,t take their dogs for a walk. In the UK, ...
(Date:8/25/2014)... old saying in the biofuels industry: "You can ... a new study may pave the way to ... Department,s National Renewable Energy Laboratory (NREL) demonstrates a ... of lignin into a variety of renewable fuels, ... , " Lignin Valorization Through Integrated Biological Funneling ...
(Date:8/25/2014)... of proteins that promotes virus entry into cells also ... and other viruses, University of Missouri researchers have found. ... insights into our understanding of not only HIV infection, ... Shan-Lu Liu, M.D., Ph.D., associate professor in the MU ... , The study was recently published in the ...
Breaking Biology News(10 mins):Education and dog-friendly neighbourhoods could tackle obesity 2New process helps overcome obstacles to produce renewable fuels and chemicals 2MU researchers discover protein's ability to inhibit HIV release 2MU researchers discover protein's ability to inhibit HIV release 3
... Saskatchewan's Vaccine and Infectious Disease Organization (VIDO) have developed a ... fight against a disease for which no vaccines are yet ... that this vaccination technique may be effective against HCV. The ... , The team, funded by the Canadian Institutes of ...
... and the Department of Horticulture in the College ... have developed a new procedure for the efficient ... of strawberry. The scientists have used Agrobacterium tumefaciens, ... woodland or alpine strawberry Fragaria vesca. , ...
... of molecule which they believe could ultimately lead to ... modified tobacco. Writing in Plant Biotechnology Journal, Dr Patricia ... along with researchers at the University of Warwick say ... far frustrated attempts to turn plants into economically viable ...
Cached Biology News:U of S researchers develop new vaccine candidate against hepatitis C 2Strawberries by design 2Do plants have the potential to vaccinate against HIV? 2
... Sheep polyclonal to Decorin ( ... Antigen: Synthetic ... to amino acids 6-19 of Human ... molecule bone proteoglycan II). ...
... VSOS-4P, all Programmable and Digital Orbital Shaker. Our ... redesigned to make every day use even easier. ... for up to 4 different programs. Its easy ... program. Furthermore, the VSOS-4P has a pulse operation ...
... enables early selection of the best ... quantitative data for sensitivity, dynamic range, ... Furthermore quantitative antibody fingerprints can be ... your antibodies., The full-service package includes ...
... is a new generation of microarrays to ... enables you to rapidly elucidate alternatively spliced ... relevant for drug discovery. The service combines ... design and customized analysis with Agilents robust ...
Biology Products: